NO20084024L - Imidazolbaserte forbindelser, preparater omfattende slike, og anvendelse av slike - Google Patents

Imidazolbaserte forbindelser, preparater omfattende slike, og anvendelse av slike

Info

Publication number
NO20084024L
NO20084024L NO20084024A NO20084024A NO20084024L NO 20084024 L NO20084024 L NO 20084024L NO 20084024 A NO20084024 A NO 20084024A NO 20084024 A NO20084024 A NO 20084024A NO 20084024 L NO20084024 L NO 20084024L
Authority
NO
Norway
Prior art keywords
imidazole
based compounds
preparations
compounds
disorders
Prior art date
Application number
NO20084024A
Other languages
English (en)
Inventor
David J Augeri
Kenneth G Carson
Jeffrey Bagdanoff
Lakmal W Boteju
Theodore C Jessop
David Kimball
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of NO20084024L publication Critical patent/NO20084024L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Imidazolbaserte forbindelser, preparater omfattende disse og anvendelse av dem ved behandling, forhindring og kontroll av inflammatoriske og autoimmune sykdommer og lidelser. Bestemte forbindelser har formel I:
NO20084024A 2006-02-24 2008-09-22 Imidazolbaserte forbindelser, preparater omfattende slike, og anvendelse av slike NO20084024L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77647306P 2006-02-24 2006-02-24
US81522106P 2006-06-20 2006-06-20
US11/698,253 US7649098B2 (en) 2006-02-24 2007-01-25 Imidazole-based compounds, compositions comprising them and methods of their use
PCT/US2007/004648 WO2007100617A2 (en) 2006-02-24 2007-02-21 Imidazole-based compounds, compositions comprising them and methods of their use

Publications (1)

Publication Number Publication Date
NO20084024L true NO20084024L (no) 2008-11-06

Family

ID=38320192

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084024A NO20084024L (no) 2006-02-24 2008-09-22 Imidazolbaserte forbindelser, preparater omfattende slike, og anvendelse av slike

Country Status (20)

Country Link
US (3) US7649098B2 (no)
EP (2) EP2010501B1 (no)
JP (1) JP5153655B2 (no)
KR (1) KR20080096570A (no)
AU (1) AU2007221265B2 (no)
BR (1) BRPI0710076A2 (no)
CA (1) CA2643021C (no)
DK (1) DK2010501T3 (no)
EA (1) EA015783B1 (no)
EC (1) ECSP088692A (no)
ES (1) ES2456673T3 (no)
IL (1) IL193297A (no)
MX (1) MX2008010772A (no)
NO (1) NO20084024L (no)
NZ (1) NZ570308A (no)
PL (1) PL2010501T3 (no)
PT (1) PT2010501E (no)
SG (1) SG170024A1 (no)
WO (1) WO2007100617A2 (no)
ZA (1) ZA200806842B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102097458B (zh) 2004-06-04 2013-10-30 伊利诺伊大学评议会 用于制造并组装可印刷半导体元件的方法和设备
TW200848029A (en) 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
AR065980A1 (es) * 2007-04-12 2009-07-15 Lexicon Pharmaceuticals Inc Metodos para preparar compuestos basados en imidazol
TWI412362B (zh) * 2007-04-12 2013-10-21 Lexicon Pharmaceuticals Inc （ｅ）-１-（４-（（１ｒ，２ｓ，３ｒ）-１，２，３，４-四羥丁基）-１ｈ-咪唑-２-基）乙酮肟的固體形式
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
NZ588737A (en) * 2008-03-31 2012-05-25 Univ Columbia Methods of diagnosing, preventing and treating bone mass diseases
ES2401555T3 (es) * 2008-06-18 2013-04-22 Lexicon Pharmaceuticals, Inc. Formas sólidas de (1R,2S,3R)-1-(2-(isoxazol-3-il)-1H-imidazol-4-il)butano-1,2,3,4-tetraol y métodos de utilización de las mismas
TW201002698A (en) * 2008-06-18 2010-01-16 Lexicon Pharmaceuticals Inc Methods of preparing imidazole-based bicyclic compounds
SI2326621T1 (sl) 2008-07-23 2016-10-28 Arena Pharmaceuticals, Inc. Substituirani derivati 1,2,3,4-tetrahidrociklopenta(b)indol-3-il)ocetne kisline, uporabni pri zdravljenju avtoimunskih in vnetnih motenj
SI2342205T1 (sl) 2008-08-27 2016-09-30 Arena Pharmaceuticals, Inc. Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj
AR074062A1 (es) * 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de la malaria cerebral y forma farmaceutica
AR074061A1 (es) * 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Inhibidores de s1p liasa para el tratamiento de la malaria cerebral y formulacion farmaceutica
EP2493861A1 (en) 2009-10-26 2012-09-05 Lexicon Pharmaceuticals, Inc. Methods of preparing 1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
WO2011102404A1 (ja) 2010-02-18 2011-08-25 第一三共株式会社 イミダゾール誘導体
SG10201501575VA (en) 2010-03-03 2015-04-29 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2586874B1 (en) 2010-06-28 2015-04-22 Daiichi Sankyo Company, Limited Method for screening for s1p lyase inhibitor using cultured cell
WO2013002248A1 (ja) 2011-06-28 2013-01-03 第一三共株式会社 リン酸エステル誘導体
WO2013049272A2 (en) 2011-09-29 2013-04-04 Theraceutix, Llc Composition and method for treatment of symptoms associated with various skin conditions
TR201302590A2 (tr) * 2013-03-04 2014-09-22 S Gueniz Kuecuekguezel Diflunisalden hareketle yeni bileşiklerin sentezi.
CN107405332A (zh) 2015-01-06 2017-11-28 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
CA3002551A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders
EP3582814B1 (en) 2017-02-16 2024-05-01 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
AU2018270772B2 (en) 2017-05-16 2024-06-06 Generos Biopharma Ltd. Compositions and methods for treating rheumatoid arthritis
EP3443986A1 (en) * 2017-08-17 2019-02-20 AC BioScience Enhancement of chemotherapy efficiency by sphingosine-1-phosphate
EP3847158A1 (en) 2018-09-06 2021-07-14 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788548A (fr) * 1971-09-10 1973-03-08 Bayer Ag Nouveaux acides 2-imidazolyl-carbonyl-benzoiques, leurs esters et leur sels, leur procede de preparation et leur application comme regulateursde croissance des vegetaux
US4567194A (en) * 1983-03-10 1986-01-28 The Coca-Cola Company 2-Acylimidazole compounds, their synthesis and use as medicinal agents
US4614662A (en) * 1985-08-26 1986-09-30 D. D. Williamson & Co., Inc. Fast cook-continuous process for production of ammonia caramel color
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU2594092A (en) 1991-09-26 1993-04-27 Smithkline Beecham Plc Antibacterial, antimycoplasmal compounds related to mupirocin
GB9201391D0 (en) 1992-01-22 1992-03-11 Smithkline Beecham Plc Method of treatment
DE4205081A1 (de) 1992-02-20 1993-08-26 Bayer Ag 1-acyloxy-2-azolyl-ethane
US5324840A (en) * 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5519040A (en) * 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
SE9401965D0 (sv) * 1994-06-07 1994-06-07 Astra Ab New compounds
US6420522B1 (en) * 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
CA2195847A1 (en) * 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
BR9509024A (pt) * 1994-09-26 1997-09-30 Shionogi & Co Derivados de imidazol
JPH08151386A (ja) 1994-09-27 1996-06-11 Takeda Chem Ind Ltd 複素環エチルチオセフェム化合物、その製造法および抗菌組成物
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
FR2743366B1 (fr) * 1996-01-10 1998-02-06 Rhone Poulenc Rorer Sa Derives de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one, leur preparation, leurs intermediaires et les medicaments les contenant
AU2881797A (en) 1996-05-31 1998-01-05 University Of Wollongong, The Acetyl derivatives of thiazoles and analogues
US6207371B1 (en) 1996-10-04 2001-03-27 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6139833A (en) 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
US6136566A (en) 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
KR100799134B1 (ko) * 1999-05-24 2008-01-29 미츠비시 웰파마 가부시키가이샤 페녹시프로필아민 화합물
JP4156807B2 (ja) 1999-06-01 2008-09-24 エラン ファーマ インターナショナル，リミティド 小型ミル及びその方法
DE10025672A1 (de) 2000-05-24 2001-11-29 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
US6858383B2 (en) * 2000-12-22 2005-02-22 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
DE10111936C1 (de) * 2001-03-13 2002-10-02 Wella Ag N-Heteroarylmethyl-m-phenylendiamin-Derivate enthaltende Haarfärbemittel sowie neue N-Heteroarylmethyl-m-phenylendiamin-Derivate
AU2002312230A1 (en) 2001-06-05 2002-12-16 Elan Pharma International Limited System and method for milling materials
US6976647B2 (en) 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
DE10130145A1 (de) * 2001-06-22 2003-01-02 Wella Ag Kationische Farbstoffe, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Färbemittel
PT1424330E (pt) * 2001-08-10 2011-12-22 Nippon Chemiphar Co Activador do receptor ä responsivo a proliferadores peroxissomais
WO2003022274A2 (en) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 2-aroylimidazole compounds for treating cancer
US6692960B2 (en) * 2001-09-28 2004-02-17 Isis Pharmaceuticals, Inc. Antisense modulation of sphingosine-1-phosphate lyase expression
ATE487470T1 (de) 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
MXPA06007054A (es) * 2003-12-19 2007-04-17 Elixir Pharmaceuticals Inc Metodos para tratar una enfermedad.
CA2553670A1 (en) * 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
AU2005219737B2 (en) * 2004-03-05 2009-11-19 Taisho Pharmaceutical Co., Ltd. Thiazole derivative
TW200848029A (en) 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
TWI412362B (zh) 2007-04-12 2013-10-21 Lexicon Pharmaceuticals Inc （ｅ）-１-（４-（（１ｒ，２ｓ，３ｒ）-１，２，３，４-四羥丁基）-１ｈ-咪唑-２-基）乙酮肟的固體形式
TW200920355A (en) 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders

Also Published As

Publication number Publication date
EP2010501A2 (en) 2009-01-07
US8404732B2 (en) 2013-03-26
EA015783B1 (ru) 2011-12-30
CA2643021C (en) 2015-04-07
CA2643021A1 (en) 2007-09-07
US20100076030A1 (en) 2010-03-25
MX2008010772A (es) 2008-09-01
ECSP088692A (es) 2008-11-27
US20070208063A1 (en) 2007-09-06
AU2007221265A1 (en) 2007-09-07
ES2456673T3 (es) 2014-04-23
NZ570308A (en) 2010-09-30
US7649098B2 (en) 2010-01-19
US8093267B2 (en) 2012-01-10
EP2090334B1 (en) 2015-04-29
JP2009527564A (ja) 2009-07-30
WO2007100617A3 (en) 2008-01-17
DK2010501T3 (da) 2014-06-30
US20130005775A1 (en) 2013-01-03
IL193297A (en) 2013-03-24
ZA200806842B (en) 2009-12-30
PL2010501T3 (pl) 2014-09-30
AU2007221265B2 (en) 2012-08-02
EA200870292A1 (ru) 2009-02-27
IL193297A0 (en) 2009-08-03
BRPI0710076A2 (pt) 2011-08-02
SG170024A1 (en) 2011-04-29
EP2090334A2 (en) 2009-08-19
WO2007100617A2 (en) 2007-09-07
EP2010501B1 (en) 2014-04-02
JP5153655B2 (ja) 2013-02-27
PT2010501E (pt) 2014-05-07
EP2090334A3 (en) 2009-09-23
KR20080096570A (ko) 2008-10-30

Similar Documents

Publication Publication Date Title
NO20084024L (no) Imidazolbaserte forbindelser, preparater omfattende slike, og anvendelse av slike
EA201170521A1 (ru) Новые соединения
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
HK1130794A1 (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
MX2009009190A (es) Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
WO2008011392A8 (en) Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
TW200714604A (en) Substituted heterocycles and the uses thereof
MY147247A (en) Organic compounds and their uses
SG161318A1 (en) Heterocyclic inhibitors of mek and methods of use thereof
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
MX2007011493A (es) Modalidades antiinflamatorias.
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
WO2006079068A3 (en) Compositions and methods for studying and treating inflammatory diseases and disorders
WO2010077310A3 (en) Amide derivatives of ethacrynic acid
MX2010005915A (es) Derivados de fenil-oxetanilo.
MX2009006457A (es) Metodos y composiciones para el tratamiento de enfermedades de fibrosis relacionadas con interleucina-4 o interleucina-13.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application